SNF1-related protein kinase family (SNRK) inhibitors represent a distinct class of chemical compounds that target a crucial cellular signaling pathway. The SNF1-related protein kinase, an ortholog of the mammalian AMP-activated protein kinase (AMPK), plays a pivotal role in cellular energy homeostasis. Members of the SNF1-related protein kinase family are conserved across eukaryotic organisms, regulating diverse cellular processes, including metabolism, growth, and response to environmental stress. SNF1-related protein kinases are activated in response to energy depletion, promoting cellular adaptation and survival under conditions of nutrient scarcity or metabolic stress.
Inhibitors of SNF1-related protein kinases, commonly referred to as SNF1 inhibitors, are designed to modulate the activity of these kinases and consequently impact the downstream signaling cascades. By interfering with the kinase activity, these inhibitors may influence cellular processes associated with energy balance, making them potential tools for elucidating the molecular mechanisms underlying metabolic regulation. Researchers utilize SNF1 inhibitors in experimental settings to probe the intricate network of cellular responses to nutrient availability and stress. The development and study of SNF1 inhibitors contribute to our understanding of fundamental cellular biology, shedding light on the intricate pathways that govern energy sensing and utilization across diverse organisms.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib selectively binds to the ATP-binding site of BRAF V600E mutant kinase, inhibiting its activity. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Dabrafenib targets and inhibits several BRAF kinase isoforms, including V600E, V600K, and V600D. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that works downstream of BRAF in the MAPK pathway, thereby inhibiting BRAF signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases including BRAF, thereby inhibiting tumor cell proliferation and angiogenesis. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib selectively inhibits MEK1/2, acting downstream of BRAF to prevent activation of the MAPK pathway. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
Encorafenib selectively targets and inhibits BRAF V600E as well as wild-type BRAF and CRAF kinases. | ||||||
Dexmedetomidine hydrochloride | 145108-58-3 | sc-205290 sc-205290A | 10 mg 50 mg | $162.00 $500.00 | ||
MLN2480 is a pan-RAF inhibitor that can inhibit BRAF-driven signaling pathways in cells. | ||||||
RAF265 | 927880-90-8 | sc-364599 | 5 mg | $191.00 | ||
RAF265 inhibits both BRAF and VEGFR2, which may lead to decreased tumor vascularization and growth. | ||||||
SB 590885 | 405554-55-4 | sc-363287 sc-363287A | 10 mg 50 mg | $223.00 $942.00 | ||
SB590885 is a potent BRAF kinase inhibitor with selectivity for the BRAF V600E mutant over wild-type. | ||||||